Prevalence of Hepatitis C virus Genotype 3a in patients with Hodgkin and Non-Hodgkin Lymphoma
-
Hashem Radmehr
,
Manoochehr Makvandi
,
Alireza Samarbafzadeh
,
Ali Teimoori
,
Niloofar Neisi
,
Mojtaba Rasti
,
Sara Abasifar
,
Hasan Soltani
,
Samaneh Abbasi
,
Hadis Kiani
,
Hamide Mehravaran
,
Azarakhsh Azaran
,
Toran Shahani
Abstract
Background and Objectives: Hepatitis C virus (HCV) is a major public health problem worldwide. Replication and persistence of HCV genome have been described in the liver tissue as well as B cells lymphocyte. Several investigations have reported that long-term persistence of HCV in B cells may result in Hodgkin and Non-Hodgkin lymphoma. This study was aimed to determine frequency of HCV RNA in histological tissues obtained from patients suffered from Hodgkin and Non-Hodgkin lymphoma.
Materials and Methods: 52 formalin-fixed paraffin-embedded tissue blocks including 23 (44.3%) Hodgkin and 29 (55.7%) Non-Hodgkin samples were collected and five micrometer sections were prepared. RNA was extracted and cDNA was synthesized. Two consecutive Nested RT-PCR assays were carried out for detection of HCV 5’ UTR and core gene. RT-PCR products were sequenced and aligned to construct HCV phylogenic tree to evaluate the homology of sequences in comparison to the reference sequences retrieved from Genbank.
Results: Overall, 6 Non-Hodgkin (20.6%) and 3 Hodgkin lymphoma (13.04%) samples showed positive PCR results for both 5’ UTR and HCV core RNA via nested PCR (P<0.469). Sequencing results revealed that all detected HCV RNA samples belonged to the genotype 3a.
Conclusion: Despite low prevalence of HCV infection in Iran, high frequency of HCV RNA genotypes 3a (17.3%) has been found in patients with Hodgkin and Non-Hodgkin lymphoma. To improve treatment regimens, screening of HCV RNA in patients suffered from Hodgkin or Non-Hodgkin lymphoma is recommended which can be done through highly sensitive molecular means before and after immunosuppression status.
Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61:S45-57.
Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-538.
Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Ex- pert Rev Vaccines 2011; 10:659-672.
Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated cri- teria and genotype assignment web resource. Hepatol- ogy 2014; 59318-327.
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV sero- prevalence. Hepatology 2013; 57:1333-1342.
Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Ira- nian Med 2005; 8: 84-90.
Machida K, McNamara G, Cheng KT, Huang J, Wang CH, Comai L, et al. Hepatitis C virus inhibits DNA damage repair through reactive oxygen and nitrogen species and by interfering with the ATM-NBS1/Mre11/ Rad50 DNA repair pathway in monocytes and hepato- cytes. J Immunol 2010; 185:6985-6998.
Deng L, Nagano-Fujii M, Tanaka M, Nomura-Takiga- wa Y, Ikeda M, Kato N, et al. NS3 protein of Hepatitis C virus associates with the tumour suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. J Gen Virol 2006; 87:1703-1713
Canioni D, Michot JM, Rabiega P, Molina TJ, Charlotte F, Lazure T, et al. In Situ Hepatitis C NS3 protein de- tection is associated with high grade features in Hep- atitis C-Associated B-Cell Non-Hodgkin lymphomas. PLoS One 2016; 11:e0156384.
Peveling-Oberhag J, Arcaini L, Hansmann ML, Ze- uzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 2013; 59:169-177.
Armitage JO. Early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363:653-662.
Gandhi MK, Tellam JT, Khanna R. Epstein-Barr vi- rus-associated Hodgkin's lymphoma. Br J Haematol 2004; 125:267-281.
Bagirath PV, Kumar JV, Arvind UD, Shailaja G. Ag- gressive extranodal peripheral T-cell non-Hodgkin's lymphoma: A rare case report and review. J Oral Max- illofac Pathol 2014; 18:80-83.
Morton LM. Dissecting lymphoma incidence to inform epidemiologic and clinical research. Leuk Lymphoma 2013; 54:1575-1576.
Yenice N, Gulluk F, Arican N, Turkmen S. HCV preva- lence in Hodg¬kin and non-Hodgkin lymphoma cases. Turk J Gasteroenterol 2003; 14:173-176.
Pozzato G, Mazzaro C, Crovatto M, Modolo ML, Ce- selli S, Mazzi G, et al. Low-grade malignant lympho- ma, hepatitis C virus infection, and mixed cryoglobu- linemia. Blood 1994; 84:3047-3053.
Economides MP, Mahale P, Turturro F, Hosry J, Sa- maniego F, Granwehr BP, et al. Development of non-Hodgkin lymphoma as a second primary cancer in hepatitis C virus-infected patients with a different pri- mary malignancy. Leuk Lymphoma 2017; 58:485-488.
Michot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lym- pho-C study. Am J Hematol 2015; 90:197-203.
Makvandi M, Khalaf khany D, Rasti M, Neisi N, Omid- varinia A, Mirghaed A, et al. Detection of Hepatitis C virus RNA in peripheral blood mononuclear cells of patients with abnormal alanine transaminase in Ahvaz. Indian J Med Microbiol 2014; 32:251-255.
Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K,Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997; 35:201-207.
Keresztes K, Takács M, Horányi M, Miltényi Z, Illés Á. HCV and HGV Infection in Hodgkin’s Disease. Pathol Oncol Res 2003; 9:222-225.
Dal Maso L, Talamini R, Montella M, Crovatto M, Franceschi S. Hepatitis B and C viruses and Hodgkin lymphoma: a case-control study from Northern and Southern Italy. Haematologica 2004; 89:ELT17.
Iqbal T, Mahale P, Turturro F, Kyvernitakis A, Torres HA. Prevalence and association of hepatitis C virus in- fection with different types of lymphoma. Int J Cancer 2016;138:1035-1037.
Cowgill KD, Loffredo CA, Eissa SA, Mokhtar N, Ab- del-Hamid M, Fahmy A, et al. Case-control study of non-Hodgkin's lymphoma and hepatitis C virus infec- tion in Egypt. Int J Epidemiol 2004; 33:1034-1039.
Spinelli JJ, Lai AS, Krajden M, Andonov A, Gascoyne RD, Connors JM, et al. Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada. Int J Cancer 2008; 122:630-633.
Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, San- paolo MG, et al. Hepatitis C virus and B-cell non-Hod- gkin lymphomas: an Italian multicenter case-control study. Blood 2003; 102:996-999.
Khodabandehloo M, Roshani D. Prevalence of hepati- tis C virus genotypes in Iranian patients: a systematic review and meta-analysis. Hepat Mon 2014; 14:e22915.
Farshadpour F, Makvandi M, Samarbafzadeh AR, Jalalifar MA. Determination of hepatitis C virus gen- otypes among blood donors in Ahvaz, Iran. Indian J Med Microbiol 2010; 28:54-56.
Visco C, Finotto S. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treat- ment. World J Gastroenterol 2014; 20:11054-11061.
Mazzaro C, De Re V, Spina M, Dal Maso L, Festini G, Comar C, et al. Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol 2009; 145:255-257.
Pellicelli AM, Zoli V. Role of ribavirin in hepatitis flare in HCV-infected patients with B cell non Hodgkin’s lymphoma treated with rituximab-containing regi- mens. Dig Liver Dis 2011;43:501-502.
| Files | ||
| Issue | Vol 8 No 6 (2016) | |
| Section | Articles | |
| Keywords | ||
| Nested. RT-PCR Hepatitis C virus Hodgkin lymphoma Non-Hodgkin lymphoma Genotype | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
